From the Departments of Infectious and Tropical Diseases and

We screened 192 patients infected with human immunodeficiency virus (HIV) to examine the relation between CD4+ lymphocyte counts and cytomegalovirus (CMV) viremia and the occurrence of CMV disease and subsequent duration of survival. When we stratified the viremic patients by CD4+lymphocyte counts, the proportions were as follows: <50/mm3, 20 (25%) of 80 patients; 50-100/mm3, 2 (5.5%) of 36; 101-150/mm3, none of 14; and>150/mm3, 1 (1.5%) of 62. After a mean follow-up period of 8.5 months, 21 (11%) of 192 patients developed CMV disease. The probability of developing CMV disease at 6 months was 13 % when the CD4+ lymphocyte count was <50/mm3, 3 % when the CD4+ lymphocyte count was 50-100/mm3, and 0 when the CD4+ lymphocyte count was>100/mm3; this probability was 46 % for viremic patients and 1 % for nonviremic patients. In a multivariate analysis, CMV viremia was independently prognostic of CMV disease (relative risk, 22.03; 95 % confidence interval, 6.49-78.97; P <.001), whereas a CD4+ lymphocyte count of <50/mm3 was not (P =.26). These results support the value of CMV viremia for predicting which HIV-infected patients are at risk of developing CMV disease and should therefore receive primary prophylaxis. Cytomegalovirus (CMV) disease is an important cause of morbidity and mortality among patients with advanced. HI